News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
The provided content is not an article but rather a privacy notice or a placeholder. It does not contain any information about Insight Molecular Diagnostics or its Q2 earnings. Therefore, no meaningful summary can be generated.
Sharemaestro market context Trend signal active 52 weeks +31.8% · Next-week setup positive 58.1%This article announces the filing of a Form 8K by Insight Molecular Diagnostics Inc. on August 10. The filing is a standard regulatory announcement, and the article provides no further details beyond the company name and filing date. It appears to be a placeholder …
Insight Molecular Diagnostics (IMDX) reported a steep revenue drop in Q2 2026, with net revenue down sharply to $239,000 from $518,000 in the prior year, and a net loss of $11.3 million. Despite the revenue decline and increased operating expenses, the company bolstered its …
Insight Molecular Diagnostics Inc. (IMDX) reported its Q2 2026 results and provided an update on the FDA review of its GraftAssureDx product. The company is progressing with the FDA, expecting marketing authorization soon, and highlighted favorable Medicare reimbursement policy changes. IMDX also shared clinical …
QIAstat-Dx BCID GPF Plus AMR Panel detects 20 pathogen targets and 10 antimicrobial resistance markers from positive blood cultures in about one hour FDA clearance marks QIAGEN's entry into U.S. bloodstream infection testing and establishes the first member of a planned QIAstat-Dx BCID panel …
Sharemaestro market context Price above Trend Line 52 weeks -14.1%IAMGOLD Corporation announced the completion of the sale of its indirect 35% interest in the Bambadji Joint Venture and its attributable interest in the Bambadji Sud exploration permit in Senegal to Fortuna Mining Corp. The transaction generated approximately $70 million in cash proceeds for …
An Indian regulator has confiscated liquor bottles from Diageo due to concerns over packaging safety. This action follows previous warnings to Diageo by Indian authorities regarding misleading claims about whisky aging. The event highlights ongoing scrutiny of product standards and advertising practices for alcoholic …
National Bank has increased its price target for Iamgold Corp. to C$32.00 per share, up from the previous C$31.00. This adjustment was reported by Dow Jones and sourced from Baystreet.ca, indicating a positive outlook from the analyst firm.
TD Cowen has increased its price target for Diageo PLC (NYSE:DEO) shares to GBP20.40 from GBP17.50, maintaining a Buy rating, following the spirits maker's Capital Markets Day. The firm believes Diageo's updated roadmap signals improved growth potential through self-help initiatives, even amid subdued U.S. …
Have you assessed how the international operations of Qiagen (QGEN) performed in the quarter ended June 2026? For this diagnostic products maker, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects. …
Sharemaestro market context Price above Trend Line 52 weeks -14.1%Brokers are divided on Diageo's prospects following its capital markets day. Jefferies raised its price target to 2,200p, citing a credible plan and potential for mid-single-digit profit growth and future share buybacks. UBS maintained a 'neutral' rating and a 1,600p target, expressing skepticism about …
Diageo's share price has risen 11% in the last week, prompting speculation of a rebound despite continued sales struggles. The company, under new CEO Dave Lewis, is implementing an ambitious turnaround strategy focusing on cost savings, dividend cuts, and a revitalized product portfolio to …
This article provides an overview of Insight Molecular Diagnostics Inc. (IMDX) stock, including its current price, market capitalization, key financial stats, and performance over various periods. It also highlights analyst opinions, future earnings expectations, and company details, noting the FDA review for GraftAssureDx and …
UBS has reaffirmed its "Neutral" rating for Diageo plc, maintaining a target price of GBX 1600. The report notes that European stocks closed mixed, with India's regulator confiscating Diageo liquor bottles over packaging safety concerns. The article also provides an overview of Diageo's company …
Insight Molecular Diagnostics (NASDAQ: IMDX) reported second-quarter EPS of $-0.230, exceeding analyst estimates of $-0.240. However, the company's revenue of $240K fell short of the consensus estimate of $470.85K. Despite the revenue miss, the company's stock price has shown significant volatility, being down -25.700% …
This page displays the "Price to sales forward" financial metric for Lucid Diagnostics Inc. (NASDAQ: LUCD). It indicates that the market is closed, with no trades currently. The information is provided by TradingView, with market data from ICE Data Services and reference data from …
Diageo plc (DGE) is initiating a multi-year restructuring program aiming for $1 billion in savings and anticipating $1.2 billion in charges, along with divestments and headcount reductions. The company is also preparing for leadership changes in Asia-Pacific, while facing challenges from North America weakness …
This article details IVY LANE CAPITAL MANAGEMENT, LLC's historical holdings in Quest Diagnostics Inc (DGX). As of March 31, 2026, the firm holds 29,000 shares valued at $5.68 million, representing 8.59% of its portfolio. The investment has generated an estimated gain of $4.19 million, …
Insight Molecular Diagnostics Inc (IMDX) is considered 284.7% overvalued based on its GF Value™ despite optimism around future FDA authorization for its GraftAssureDx test and expanded Medicare reimbursement. The company reported a Q2 adjusted EBITDA loss and an upward revision of its cash burn …
* Insight Molecular Diagnostics Inc. (IMDX [https://seekingalpha.com/symbol/IMDX]) is scheduled to announce Q2 earnings results on Monday, August 10th, after market close. * The consensus EPS estimate is -$0.25, [https://seekingalpha.com/symbol/IMDX/earnings/estimates] and the consensus revenue estimate is $0.44M * Over the last year, IMDX has beaten …
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. IAMGOLD (TSX:IMG) has moved into focus after reporting second quarter 2026 results that featured …
Carriage Services, Inc. (NYSE:CSV) missed analyst revenue and EPS forecasts in its latest quarterly results, leading to a slight downgrade in earnings per share predictions and an 11% reduction in the average price target to US$53.60. Despite the earnings downgrade, analysts reconfirmed revenue numbers …
IAMGOLD (TSX:IMG) stock has seen a significant multi-year return, yet analysis suggests it remains undervalued based on discounted cash flow (DCF) and P/E ratio metrics. Despite a strong Q2 update and share price reaction, the company's intrinsic value estimates indicate a notable discount to …
In the second quarter of 2026, IAMGOLD Corporation reported higher sales of US$856.9 million and net income of US$230.5 million year over year, completed a share repurchase of 28,000,000 shares for CA$510.4 million since December 2025, and earlier appointed veteran mining executive Catherine McLeod-Seltzer …
The Manufacturers Life Insurance Company recently acquired 63,219 shares of Qiagen N.V. (NYSE:QGEN) worth approximately $2.52 million. This purchase is part of broader institutional investment, with various firms like Boston Partners, Norges Bank, and Price T Rowe Associates also holding significant stakes, bringing total …
Search by ticker symbol or company name and select a result to open its chart.